Literature DB >> 2233916

Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial.

S Gagnon1, A M Boota, M A Fischl, H Baier, O W Kirksey, L La Voie.   

Abstract

BACKGROUND: Preliminary reports suggest that patients with the acquired immunodeficiency syndrome (AIDS) and Pneumocystis carinii pneumonia may benefit from the addition of corticosteroid treatment to antibiotic therapy.
METHODS: We conducted a double-blind, placebo-controlled trial to assess the efficacy of adjunctive corticosteroids in patients with AIDS and severe P. carinii pneumonia. Patients with marked abnormalities in gas exchange who had been treated with antibiotics for less than 72 hours were randomly assigned to receive either methylprednisolone (40 mg) or placebo every 6 hours for 7 days, in addition to treatment for 21 days with trimethoprim-sulfamethoxazole. The primary outcome measures were survival until hospital discharge and the development of respiratory failure.
RESULTS: Twenty-three patients were enrolled in the study; there were no significant differences in base-line clinical or laboratory measures between the two treatment groups. Of 12 patients treated with corticosteroids, 9 (75 percent) survived until hospital discharge, as compared with only 2 of 11 placebo recipients (18 percent) (P less than 0.008). Respiratory failure developed in nine placebo recipients, as compared with only three patients treated with corticosteroids (P less than 0.008). No patient required the interruption or discontinuation of corticosteroid or antibiotic treatment because of toxicity or a complicating event. Because of the marked difference in survival, it was deemed unethical to continue the trial, and the study was terminated.
CONCLUSIONS: Early adjunctive corticosteroid therapy can improve survival and decrease the occurrence of respiratory failure in patients with AIDS and severe P. carinii pneumonia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2233916     DOI: 10.1056/NEJM199011223232103

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  60 in total

1.  Pneumocystis carinii: A review of an important opportunistic pathogen in AIDS.

Authors:  M J Gill; R Read
Journal:  Can J Infect Dis       Date:  1991

Review 2.  Acute respiratory distress syndrome in traumatic brain injury: how do we manage it?

Authors:  Valentina Della Torre; Rafael Badenes; Francesco Corradi; Fabrizio Racca; Andrea Lavinio; Basil Matta; Federico Bilotta; Chiara Robba
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

Review 3.  AIDS and the lung: update 1992. 1. Pneumocystis carinii pneumonia.

Authors:  R F Miller; D M Mitchell
Journal:  Thorax       Date:  1992-04       Impact factor: 9.139

4.  Continuous positive airway pressure by face mask or mechanical ventilation in patients with human immunodeficiency virus infection and severe Pneumocystis carinii pneumonia.

Authors:  B Gachot; B Clair; M Wolff; B Régnier; F Vachon
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

Review 5.  Treatment of infection due to Pneumocystis carinii.

Authors:  J A Fishman
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

6.  General principles of antimicrobial therapy.

Authors:  Surbhi Leekha; Christine L Terrell; Randall S Edson
Journal:  Mayo Clin Proc       Date:  2011-02       Impact factor: 7.616

7.  Pneumocystis pneumonia in a non-HIV patient on chronic corticosteroid therapy: a question of prophylaxis.

Authors:  Michael J Plakke; Leena Jalota; Benjamin J Lloyd
Journal:  BMJ Case Rep       Date:  2013-03-01

Review 8.  HIV: treating Pneumocystis pneumonia (PCP).

Authors:  Richard John Bellamy
Journal:  BMJ Clin Evid       Date:  2008-07-16

9.  Prognostic factors of early fatal outcome and long-term survival in patients with Pneumocystis carinii pneumonia and acquired immunodeficiency syndrome.

Authors:  A Antinori; G Maiuro; F Pallavicini; F Valente; G Ventura; G Marasca; R Murri; E Pizzigallo; G Camilli; E Tamburrini
Journal:  Eur J Epidemiol       Date:  1993-03       Impact factor: 8.082

Review 10.  Optimal management strategies for HIV-infected patients who present with cough or dyspnea: a cost-effective analysis.

Authors:  K A Freedberg; A N Tosteson; D J Cotton; L Goldman
Journal:  J Gen Intern Med       Date:  1992 May-Jun       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.